MD Anderson, Invectys and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
June 17, 2022
June 17, 2022
HOUSTON, Texas, June 17 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 16, 2022:
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric a . . .
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric a . . .